Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline
Nanomedicine (Lond)
.
2020 Nov;15(26):2539-2542.
doi: 10.2217/nnm-2020-0290.
Epub 2020 Sep 18.
Authors
Alexsandra Conceição Apolinário
1
,
Amanda Soares Hirata
1
,
Rodrigo Dos Anjos Miguel
1
,
Leticia Veras Costa-Lotufo
1
,
Adalberto Pessoa
2
,
James J La Clair
3
,
William Fenical
4
,
Luciana Biagini Lopes
1
Affiliations
1
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
2
Department of Biochemical & Pharmaceutical Technology, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
3
Department of Chemistry & Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA.
4
Center for Marine Biotechnology & Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093, USA.
PMID:
32945726
DOI:
10.2217/nnm-2020-0290
No abstract available
Keywords:
L-asparaginase; fenretinide; nanotechnology; seriniquinone.
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antineoplastic Agents*
Drug Development
Nanotechnology
Neoplasms* / drug therapy
Substances
Antineoplastic Agents